Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines

被引:53
作者
Fuks, B
Gillard, M
Michel, P
Lynch, B
Vertongen, P
Leprince, P
Klitgaard, H
Chatelain, P
机构
[1] UCB Bioprod SA, Pharma Sector, B-1420 Braine lAlleud, Belgium
[2] UCB Res Inc, Cambridge, MA 02139 USA
[3] Free Univ Brussels, Fac Med, Dept Biochem & Nutr, B-1070 Brussels, Belgium
[4] Univ Liege, Ctr Cellular & Mol Neurobiol, B-4020 Liege, Belgium
关键词
anticonvulsant; binding; brain; levetiracetam; photoaffinity labelling;
D O I
10.1016/j.ejphar.2003.08.033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Levetiracetam (2S-(2-oxo-1-pyrrolidinyl)butanamide, KEPPRA(R)), a novel antiepileptic drug, has been shown to bind to a specific binding site located in the brain (Eur. J. Pharmacol. 286 (1995) 137). To identify the protein constituent of the levetiracetam binding site in situ, we synthesized the photoaffinity label [H-3]ucb 30889 ((2S)-2-[4-(3-azidophenyl)-2-oxopyrrolidin-1-yl]butanamide), a levetiracetam analog with higher affinity for the levetiracetam binding site. This radioligand was used to map the levetiracetam binding site within the brain and to study its cellular and subcellular distribution. Autoradiography experiments using [H-3]ucb 30889 in rat brain revealed a unique distribution profile that did not match that of classical receptors known to be involved in the generation of epileptic seizures. There was a high level of binding in the dentate gyrus, the superior colliculus, several thalamic nuclei, the molecular layer of the cerebellum and to a lesser extent in the cerebral cortex, the striatum and the hypothalamus. The levetiracetam binding site was restricted to neuronal cell types, undifferentiated PC 12 cells and was highly enriched in synaptic vesicles. [H-3]ucb 30889 was also used in photoaffinity labelling studies and shown to bind covalently to a membrane protein with a molecular weight of approximately 90 kDa. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:11 / 19
页数:9
相关论文
共 25 条
[1]   Regional mapping of low-affinity kainate receptors in mouse brain using [3H](2S,4R)-4-methylglutamate autoradiography [J].
Bailey, A ;
Kelland, EE ;
Thomas, A ;
Biggs, J ;
Crawford, D ;
Kitchen, I ;
Toms, NJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 431 (03) :305-310
[2]   Measurement of the dynamics of exocytosis and vesicle retrieval at cell populations using a quartz crystal microbalance [J].
Cans, AS ;
Höök, F ;
Shupliakov, O ;
Ewing, AG ;
Eriksson, PS ;
Brodin, L ;
Orwar, O .
ANALYTICAL CHEMISTRY, 2001, 73 (24) :5805-5811
[3]   Calcium regulation of exocytosis in PC12 cells [J].
Chen, YA ;
Scales, SJ ;
Duvvuri, V ;
Murthy, M ;
Patel, SM ;
Schulman, H ;
Scheller, RH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (28) :26680-26687
[4]   [H-3] LINOPIRDINE (DUP-996) LABELS A NOVEL BINDING-SITE IN RAT-BRAIN INVOLVED IN THE ENHANCEMENT OF STIMULUS-INDUCED NEUROTRANSMITTER RELEASE - AUTORADIOGRAPHIC LOCALIZATION STUDIES [J].
DESOUZA, EB ;
RULE, BL ;
TAM, SW .
BRAIN RESEARCH, 1992, 582 (02) :335-341
[5]  
GILLARD M, 2003, IN PRESS EUR J PHARM
[6]   CHARACTERIZATION OF THE PHARMACOLOGY AND REGIONAL DISTRIBUTION OF (S)-[H-3]-5-FLUOROWILLARDIINE BINDING IN RAT-BRAIN [J].
HAWKINS, LM ;
BEAVER, KM ;
JANE, DE ;
TAYLOR, PM ;
SUNTER, DC ;
ROBERTS, PJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (03) :2033-2039
[7]   Levetiracetam: A novel antiepileptic drug [J].
Hovinga, CA .
PHARMACOTHERAPY, 2001, 21 (11) :1375-1388
[8]   Autoradiographic visualization of group III metabotropic glutamate receptors using [3H]-L-2-amino-4-phosphonobutyrate [J].
Hudtloff, C ;
Thomsen, C .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (05) :971-977
[9]   NMDA AND KAINIC ACID RECEPTORS HAVE A COMPLEMENTARY DISTRIBUTION TO AMPA RECEPTORS IN THE HUMAN CEREBELLUM [J].
JANSEN, KLR ;
FAULL, RLM ;
DRAGUNOW, M .
BRAIN RESEARCH, 1990, 532 (1-2) :351-354
[10]   Interactions between presynaptic Ca2+ channels, cytoplasmic messengers and proteins of the synaptic vesicle release complex [J].
Jarvis, SE ;
Zamponi, GW .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (10) :519-525